

# Raymond R Mattingly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3917094/publications.pdf>

Version: 2024-02-01

22  
papers

676  
citations

687363

13  
h-index

839539

18  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1121  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. PLoS ONE, 2021, 16, e0252314.	2.5	3
2	Modeling Tumor: Lymphatic Interactions in Lymphatic Metastasis of Triple Negative Breast Cancer. Cancers, 2021, 13, 6044.	3.7	1
3	In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 1-15.	2.7	29
4	Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer. Cancer and Metastasis Reviews, 2019, 38, 445-454.	5.9	9
5	Ras and Rap1: A tale of two GTPases. Seminars in Cancer Biology, 2019, 54, 29-39.	9.6	121
6	Breast Cancer: Proteolysis and Migration. Advances in Experimental Medicine and Biology, 2019, 1152, 401-411.	1.6	9
7	Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Experimental Neurology, 2018, 299, 289-298.	4.1	13
8	Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia, 2018, 20, 951-963.	5.3	18
9	Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Research, 2017, 19, 56.	5.0	24
10	Phosphorylation of rat kidney Na-K pump at Ser <sup>938</sup> is required for rapid angiotensin II-dependent stimulation of activity and trafficking in proximal tubule cells. American Journal of Physiology - Cell Physiology, 2016, 310, C227-C232.	4.6	10
11	How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization. Mini-Reviews in Medicinal Chemistry, 2016, 16, 358-369.	2.4	44
12	Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer, 2015, 15, 584.	2.6	76
13	Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. ISRN Oncology, 2013, 2013, 1-14.	2.1	21
14	Angiotensin II rapidly stimulates the short-circuit current in opossum kidney cells expressing rat Na,K-ATPase. FASEB Journal, 2013, 27, 912.23.	0.5	0
15	MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression. Journal of Visualized Experiments, 2012, , .	0.3	36
16	Three-Dimensional Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 821-828.	2.5	72
17	p21-Activated Kinase 1 Coordinates Aberrant Cell Survival and Pericellular Proteolysis in a Three-Dimensional Culture Model for Premalignant Progression of Human Breast Cancer. Neoplasia, 2008, 10, 314-IN1.	5.3	76
18	Angiotensin II Increases Phosphorylation of the Na,K-ATPase at Ser <sup>943</sup> Under the Physiological Conditions Associated with Stimulation of Activity. FASEB Journal, 2008, 22, 1158.17.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Angiotensin II increases the amount of Na,K-ATPase in the plasma membrane of proximal tubule cells by phosphorylation of the $\alpha$ subunit at Ser943. FASEB Journal, 2007, 21, A1330.	0.5	0
20	The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 456-465.	2.5	63
21	Mitogen-Activated Protein Kinase Signaling in Drug-Resistant Neuroblastoma Cells. , 2003, 218, 71-84.		10
22	Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 74-81.	2.5	40